ERBB2 and bladder transitional cell carcinoma: This process is further supported by observations in bladder urothelial carcinoma, where HER2 expression in recurrent tumors differs significantly from primary lesions (30, 31), underscoring the role of immune selection in modulating HER2 status (32).